Rethinking ovarian cancer: recommendations for improving outcomes

[1]  M. Markman.  Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. , 2012, Gynecologic oncology.

[2]  M. Köbel,et al.  Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. , 2011, The Lancet. Oncology.

[3]  B. Glimelius,et al.  Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[6]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[7]  A. Tinker,et al.  Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. , 2011, Gynecologic oncology.

[8]  Gaudenz Danuser,et al.  Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. , 2011, Cancer discovery.

[9]  Gordon B Mills,et al.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.

[10]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[11]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[12]  D. Matei,et al.  Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Eisenhauer,et al.  Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. , 2011, Gynecologic oncology.

[14]  R. Drapkin,et al.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.

[15]  A. Ashworth,et al.  Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.

[16]  J. Wischhusen,et al.  The forgotten fallopian tube , 2011, Nature Reviews Cancer.

[17]  R. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[18]  Kylie L. Gorringe,et al.  IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer , 2011, Clinical Cancer Research.

[19]  S. Lele,et al.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal , 2011, Cancer.

[20]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[21]  M. Jimenez-Linan,et al.  Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer , 2010, British Journal of Cancer.

[22]  A. Harris,et al.  Biomarkers to predict the clinical efficacy of bevacizumab in cancer. , 2010, The Lancet. Oncology.

[23]  Kylie L. Gorringe,et al.  Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer , 2010, PloS one.

[24]  David D. L. Bowtell,et al.  The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.

[25]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[26]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[27]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[28]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[29]  Kylie L. Gorringe,et al.  Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.

[30]  A. Ashworth,et al.  Making the best of PARP inhibitors in ovarian cancer , 2010, Nature Reviews Clinical Oncology.

[31]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[32]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[33]  Samuel Leung,et al.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2010, The American journal of surgical pathology.

[34]  Stan B. Kaye,et al.  Imaging ovarian cancer and peritoneal metastases—current and emerging techniques , 2010, Nature Reviews Clinical Oncology.

[35]  Thomas J. Hardcastle,et al.  Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma , 2010, Oncogene.

[36]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[37]  Y. Drew,et al.  Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.

[38]  A. Mantovani,et al.  Cancer and Inflammation: Implications for Pharmacology and Therapeutics , 2010, Clinical pharmacology and therapeutics.

[39]  A. Ashworth,et al.  DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1 , 2010, Cancer cell.

[40]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[41]  A. Mes-Masson,et al.  Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma , 2010, The Journal of pathology.

[42]  J. Marto,et al.  Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.

[43]  Ryan D. Morin,et al.  Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.

[44]  W. Mcguire.  Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  George Kollias,et al.  The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. , 2009, The Journal of clinical investigation.

[46]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[47]  A. Ashworth,et al.  Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 , 2009, EMBO Molecular Medicine.

[48]  Patrick O. Brown,et al.  The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection , 2009, PLoS medicine.

[49]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[50]  Naveena Singh,et al.  The clonal evolution of metastases from primary serous epithelial ovarian cancers , 2009, International journal of cancer.

[51]  Matthew Burnell,et al.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2009, Journal of Family Planning and Reproductive Health Care.

[52]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[53]  D. Huntsman,et al.  A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary , 2009, The American journal of surgical pathology.

[54]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[55]  L. Hartmann,et al.  Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor‐specific fluorescent ligands , 2008, International journal of cancer.

[56]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[57]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[58]  E. Lengyel,et al.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. , 2008, The Journal of clinical investigation.

[59]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[60]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[61]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[62]  Ian G. Campbell,et al.  High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications , 2007, Clinical Cancer Research.

[63]  U. Kees,et al.  Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. , 2007, Blood.

[64]  Kathleen R. Cho,et al.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.

[65]  I. Jacobs,et al.  Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours , 2007, The Journal of pathology.

[66]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[67]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[68]  N. Urban,et al.  Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[71]  D. Xing,et al.  A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Jeffrey S. Morris,et al.  Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. , 2005, Journal of the National Cancer Institute.

[73]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[74]  Chung-Liang Ho,et al.  Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.

[75]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[76]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[77]  M. Friedlander,et al.  Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[79]  G. Coukos,et al.  TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  Barbara C Vanderhyden,et al.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. , 2003, Cancer research.

[81]  L. Morrison,et al.  Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.

[82]  R. Young,et al.  The Distinction Between Primary and Metastatic Mucinous Carcinomas of the Ovary: Gross and Histologic Findings in 50 Cases , 2003, The American journal of surgical pathology.

[83]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[84]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[85]  H. Varmus,et al.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. , 2002, Cancer cell.

[86]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[87]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.